Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1401

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 14
Chunk 1401
---
) Vice Chairman of the board of directors of the Company from February 2024 to September 2024, and (iii) the Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024. 

NOTE
15 – SUBSEQUENT EVENTS

On January 6, 2025, 625 Series
A Preferred Warrants were exercised into 625 shares of Series A Preferred Stock for gross cash proceeds of $500,000.

On January 6, 2025, the Company issued warrants to purchase an aggregate
of 163,853 shares of Common Stock to a certain investor affiliated with each other to induce investors to exercise their Series A Preferred
Warrants for cash (the “January 2025 Common Warrants”). The January 2025 Common Warrants are initially exercisable for cash
at an initial exercise price equal to $5.82 (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and
similar events). The January 2025 Common Warrants are exercisable beginning six months after the issuance date (the “Initial Exercisability
Date”) and expiring on the third anniversary of the Initial Exercisability Date. The January 2025 Common Warrants require “buy-in”
payments to be made by us for failure to deliver any shares of Common Stock issuable upon exercise. If at the time of exercise of the
January 2025 Common Warrants, there is no effective registration statement registering the shares of the Common Stock underlying the January
2025 Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms

During the period from January
1, 2025 to April 10, 2025, 1,098 shares of Series A Preferred Stock were converted into 288,832 shares of Common Stock. The conversion
ratio was based on the Series A Certificate of Designations and reflected the applicable Alternate Conversion Price.

During the period from January
1, 2025 to April 10, 2025, 75 shares of Series B Preferred Stock were converted into 50,001 shares of Common Stock. The conversion ratio
was based on the Series B Certificate of Designations and reflected the applicable Alternate Conversion Price.

F-32

During the period from January
1, 2025 to April 10, 2025, the Company sold 290,618 shares of Common Stock of the Company pursuant to the New Keystone Purchase Agreement
for net proceeds of $1